Pot Inc. is waiting to cash in on Trump’s marijuana reclassification — but the DOJ is still dragging its feet

The US government is on the verge of relaxing its strict regulations on marijuana, potentially moving it to a “Schedule 3” classification alongside medications like codeine-laced Tylenol. This shift could open up new opportunities for the cannabis industry, which is currently valued at $70 billion.

Despite the progress, some investors are still cautious due to the lack of full federal approval for marijuana-related businesses. Major banks and credit card companies are hesitant to get involved, and US stock exchanges are reluctant to list domestic weed companies. As a result, the industry is not able to reach its full potential in terms of growth and investment.

There is speculation that the Trump administration may be hesitant to fully embrace marijuana legalization, particularly for recreational use. However, there are signs that the administration is moving in a more positive direction, with discussions around medical marijuana and potential pilot programs.

Overall, investors in the cannabis industry are hopeful for legalization, especially with recent developments like the refinancing of major pot companies’ debt. While there are still challenges ahead, such as navigating the partisan landscape in Washington, there is a sense of optimism that progress is being made towards a more cannabis-friendly environment.